Sorafenib is also approved for differentiated thyroid cancer and is an oral dual-action inhibitor of Raf-kinase and multiple tyrosine kinases including VEGFR2, VEGFR3, PDGFR, and c-kit [2]. This evidence concerns the gene KDR and thyroid gland carcinoma.